← Product Code [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX) · K061652 # PALOMAR LUX1540 HANDPIECE (K061652) _Palomar Medical Products, Inc. · GEX · Feb 27, 2007 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K061652 ## Device Facts - **Applicant:** Palomar Medical Products, Inc. - **Product Code:** [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX.md) - **Decision Date:** Feb 27, 2007 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4810 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The Palomar Lux1540 handpiece is intended for skin resurfacing procedures in addition to dermatological procedures requiring the coagulation of soft tissue. ## Device Story Lux1540 handpiece is an accessory to the StarLux Pulsed Light & Laser System; delivers 1540 nm wavelength light. System includes power source, chiller, footswitch, and umbilical-connected handpiece. Operates via fractional photothermolysis, creating a lattice pattern of microscopic islets of thermal damage in superficial skin layers. Used by physicians in clinical settings for skin resurfacing and soft tissue coagulation. Output allows controlled thermal injury to stimulate skin response. Benefits include clinical skin resurfacing outcomes. ## Clinical Evidence Clinical testing demonstrated the device performs fractional photothermolysis as intended. No new safety or effectiveness issues were identified. ## Technological Characteristics Laser surgical instrument (21 CFR 878.4810). Wavelength: 1540 nm. Delivery: Fractional photothermolysis (lattice pattern of microscopic islets). System components: Power source, chiller, footswitch, handpiece. Accessory to StarLux Pulsed Light & Laser System. ## Regulatory Identification (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon. ## Predicate Devices - Reliant Laser System (Fraxel SR Laser System) ([K042319](/device/K042319.md)) - Palomar Lux1540 handpiece ([K060301](/device/K060301.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 510(K) Summary K061652 This 510(K) Summary is being submitted in accordance with 21 CFR 807.92 Applicant: Palomar Medical Technologies, Inc. 82 Cambridge St. Burlington, MA 01803 Contact Person: Sharon Timberlake, RAC, CCRA Director of Regulatory Affairs (781) 993-2414 Preparation Date: June 12, 2006 Device Trade Name: Palomar Lux1540 Handpiece Common Name: Lux1540 Classification Name: Laser surgical instrument for use in General and Plastic Surgery and Dermatology (21 CFR 878.4810) Product Code: GEX Predicate Device: Reliant Laser System (Fraxel SR Laser System) K042319 Palomar Lux1540 handpiece K060301 System Description: The Palomar Lux1540 handpiece is an accessory to the StarLux Pulsed Light & Laser System. The handpiece delivers light with a wavelength of 1540 nm. The complete system consists of a power source, chiller, a footswitch, and a handpiece connected to the power unit with an umbilical. Intended Use: The Palomar Lux1540 handpiece is intended for skin resurfacing procedures in addition to dermatological procedures requiring the coagulation of soft tissue. Performance: Performance data was provided showing the Lux1540 is capable of performing fractional photothermolysis, i.e., creation of a pattern (lattice) of microscopic islets of damage at superficial skin layers. The results from the clinical testing demonstrated that the Lux1540 performs as clinically intended and that no new issues of safety or effectiveness were present. Substantial Equivalence: The Palomar Lux1540 Handpiece is substantially equivalent to its predicate device when indicated for skin resurfacing. The data in this application demonstrates that the Palomar Lux1540 handpiece shares the same indications for use, similar design features, functional features, and therefore is substantially equivalent FEB 27 2007 substantially equivalent to its predicate devices. {1}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES. USA [Illustration of the Department of Health and Human Services logo] Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Palomar Medical Technologies, Inc. % Ms. Sharon Timberlake, RAC, CCRA Director of Regulatory Affairs 82 Cambridge Street Burlington, Massachusetts 01803 FEB 2 7 2007 Re: K061652 Trade/Device Name: Palomar Lux 1540 Handpiece Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: November 27, 2006 Received: November 28, 2006 Dear Ms. Timberlake: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {2}------------------------------------------------ ## Page 2 - Ms. Sharon Timberlake, RAC, CCRA This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Mark N. Melkerson Director Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ ## Indications for Use 510(k) Number (if known): K061652 Device Name: PalomarLux1540 Handpiece Indications for Use: Dermatological procedures requiring the coagulation of soft tissue; Skin resurfacing procedures. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices **510(k) Number** K061652 Prescription Use X (Per 21 CFR 801.109) OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (Optional Format 1-2-96) PALOMAR MEDICAL TECHNOLOGIES, INC. LUX1540 510(K): SKIN RESURFACING --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K061652](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K061652) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com